ORLISTAT IN COMBINATION THERAPY OF OBESITY AND TYPE 2 DIABETES
https://doi.org/10.21518/2079-701X-2017-3-68-74
Abstract
Over the past years, the focus has been growing on the prevention and treatment of obesity. Obesity has long been considered not just as excess body fat but as a chronic relapsing disease, the result of energy disbalance, which develops with an increase in food intake and reduced energy expenditure and is closely associated with a number of serious complications. Orlistat (Xenical), a peripherally acting drug without systemic effects [11, 24, 27], has been widely used in pharmacological treatment of obesity. Xenical is the most well-studied medication for weight loss. More than 30,000 patients with obesity were involved in clinical trials, of which over 2,500 patients had type 2 diabetes. Till today, the drug remains a breakthrough in the treatment of overweight/obesity.
About the Authors
A. M. Mkrtumyan
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
E. V. Biryukova
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
References
1. Морбидное ожирение. Под ред. И.И. Дедова. М.: Медицинское информационное агентство, 2014.
2. Aronne LJ. Therapeutic options for modifying cardiometabolic risk factors. Am J Med., 2007, 120(3 Suppl 1): S26-34.
3. Aronne LJ, Segal RK. Adiposity and fat distribution outcome measures: assessment and clinical implications. Obes Res, 2002, 10(1): 14S-21S.
4. Björntorp P. Metabolic implications of body fat distribution. Diabetes Care, 1991, 14: 1132–1143.
5. Btay GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev 1999, 20: 805-75.
6. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med., 2003, 348(17): 1625-1638.
7. Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann NY Acad Sci, 2010, 1212: E1–E19.
8. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord, 1998, 22: 39-47.
9. Galanis DJ, Harris T, Sharp D, Petrovich H. Relative weight, weight change, and risk of coronary heart disease in the Honolulu Heart Program. Am J Epidemiol, 1998, 147: 379-86.
10. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes. Diabetes Obes Metab, 2002, 4: 415-23.
11. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy, 2000, 20: 270-9.
12. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature, 2006, 444: 840–846.
13. Pinkston MM, Poston WS, Reeves RS et al. Does metabolic syndrome mitigate weight loss in overweight Mexican American women treated for 1-year with orlistat and lifestyle modification? Eat Weight Disord, 2006, 11(1): 35-41.
14. Rahmouni K, Correia MLG, Haynes WG et al. Obesity-associated hypertension. Hypertension, 2005, 45: 9-14.
15. Richelsen B, Tonstad S, Rossner S et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care, 2007, 30(1): 27-32.
16. Rowe R, Cowx M, Poole C et al The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss. Curr Med Res Opin, 2005, 21(11): 1885-90.
17. Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patient with. J. Hypertens., 2002, 29: 1873-8.
18. Sjostrom L, Rissanen A, Andersen T et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet, 1998, 352: 167-72.
19. Torgerson JS, Hauptman J, Boldrin MN et al. Xenical in the prevention of diabetes in obese subjects (XENDOC) study, a randomized study of orlistat as an agjunct to lifestyle changes for the prevention of type 2 diabetes in obese patient. Diabetes Care, 2004, 27: 155-161.
20. Tounian P, Aggoun Y, Dubern B et al: Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet, 2001, 385: 1400-04.
21. Tremblay A, Buemann B. Exercise-training, macronutrient balance and body weight control. Int J Obes Relat Metab Disord, 1995, 19: 79-86.
22. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med, 2002, 346: 591-602.
23. Wadden TA, Foster GD. Behaviorial treatment of obesity. Med Clin North Am, 2000, 85: 441-61.
24. Wirth A. reduction of body weight and co-morbidities by orlistat: The XXL- primary Health Care Trial. Diabetes, Obesity and Metabolizm, 2005, 7: 21-7.
25. Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res., 1998, 6: 97-106.
26. Zanella MT, Uehara MH, Ribeiro AB. Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study. Arq Bras Endocrinol Metabol, 2006, 50(2): 368-76.
27. Zhou Y-H, Ma X-Q, Wu C et al. Effect of AntiObesity Drug on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2012, 7(6): e39062. doi:10.1371/journal.pone.0039062.
Review
For citations:
Mkrtumyan AM, Biryukova EV. ORLISTAT IN COMBINATION THERAPY OF OBESITY AND TYPE 2 DIABETES. Meditsinskiy sovet = Medical Council. 2017;(3):68-74. (In Russ.) https://doi.org/10.21518/2079-701X-2017-3-68-74
Views:
1208
Email this article 